droxidopa

Droxidopa A precursor of noradrenaline that is used in the treatment of parkinsonism. The racemic form (DL-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a deficit of noradrenaline as well as of dopamine in Parkinson's disease and it has been proposed that this underlies the sudden transient freezing seen usually in advanced disease. Administration of DL-threo-3,4-dihydroxyphenylserine has been claimed to result in an improvement in this phenomenon but controlled studies have failed to demonstrate improvement. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)

Molecular Formula: C₉H₁₁NO₅

InChI: InChI=1/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8+/m1/s1/f/h14H

InChIKey: InChIKey=QXWYKJLNLSIPIN-WIJHRXPYDU
SMILES: C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O

Names:
    Dops (TN)
    DOPS
    Droxidopa (JAN)
    droxidopa
    D01277
    (2R,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxy-propanoic acid
    23651-95-8

Registries:
    PubChem CID 443940
    PubChem ID 7848340